Mycosis Fungoides Market By Treatment (Topical Steroids, Mechlorethamine Gel, HDAC Inhibitors, Monoclonal Antibodies, Localized Radiation Therapy, Extracorporeal Photopheresis, Others) Growth, Future Prospects And Competitive Analysis, 2019 - 2027

Industry Outlook

The mycosis fungoides market is set to project sublime growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2019 to 2027. Mycosis fungoides occurs in 70% of the patients suffering with cutaneous T cell lymphoma (CTCL), affecting initially to the skin later the infection spreads to internal organs in the later stages of the disease. Currently combinatorial treatment regimen is employed by oncologist worldwide to subdue the clinical manifestation occurring during the course of disease. SGX301 (Soligenix, Inc.) and 0.5% naloxone hydrochloride lotion (Elorac, Inc.) are currently in the phase III clinical trials being studied for its safety and efficacy for the treatment of mycosis fungoides.    

Market Synopsis

Get a sample copy for more information

"Recent USFDA approval of Poteligeo for the treatment of mycosis fungoides will increase the demand for monoclonal antibodies treatment regime"

As per the new guidelines formulated by National Comprehension Cancer Network (NCCN), there is no permanent cure for mycosis fungoides. The treatment regimen comprises of individual and combinatorial therapy depending upon the stage and severity of the disease. Usually topical steroids and mechlorethamine gel are used as a topical treatment in the early stage of the disease, if need be localized radiation therapy is also recommended by oncologist depending upon the spread of mycosis fungoides. HDAC inhibitors and extracorporeal photopheresis are prescribed to patients in stage 2 of the disease. Monoclonal antibodies are given by systemic circulation during the late stages of mycosis fungoides. Recent approval by USFDA for Poteligeo (mogamulizumab) will further boost the demand for monoclonal antibodies as the first line of treatment for mycosis fungoides during the forecast period.

Get a sample copy for more information

"Rising incidence of mycosis fungoides and stringent treatment guidelines stipulated by USFDA drive the market growth in North America"

North America is presently ruling the regional segment for mycosis fungoides market representing a share of 31.8%. The parameters responsible for its impressive market growth are rising incidence of mycosis fungoides and stringent treatment guidelines stipulated by USFDA. The National Institute of Health (NIH), has reported the prevalence rate of mycosis fungoides in United States is ranging from 3 to 6 per 100,000 people annually. The presence of major players such as Sanofi S.A., Astellas Pharma, Soligenix, Inc., Yaupon Therapeutics etc. further bolster the market growth in North America region. Europe is in the second place holding a market share of 28.4% primarily due to favorable reimbursement scenario pertaining to treatment of mycosis fungoides in EU region. Strategic collaboration between biopharmaceutical companies and academic research institutes further strengthen the market growth in European region. Asia Pacific with a market share of 16.2% is keen to register rapid growth on account of supportive regulatory environment provided by the local healthcare agencies and proactive government policies to treat orphan and rare diseases.

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by treatment and by geography.

Biopharmaceutical giants spearheading the mycosis fungoides market are Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Sanofi SA, Soligenix, Inc., Varian Medical Systems and Yaupon Therapeutics.

Key questions answered in this report

• Who are the major biopharmaceutical companies actively engaged in the development of medicines for the treatment of mycosis fungoides?
• What are the DRO’s related to the market growth assessed as per the latest market trend?
• What is the disease pathology pertaining to mycosis fungoides and explain its different stages?
• What is the individual and combinatorial therapy employed for the treatment of mycosis fungoides?
• What is the prevalence rate of mycosis fungoides in developing regions such as Asia Pacific, MEA and LATAM?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global MF Market Portraiture
2.2. Global MF Market, by Treatment, 2018 (US$ Mn)
2.3. Global MF Market, by Geography, 2018 (US$ Mn)

Chapter 3. Mycosis Fungoides (MF) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global MF Market, by Key Players, 2018

Chapter 4. Global Mycosis Fungoides (MF) Market, by Treatment
4.1. Overview
4.2. Topical Steroids
4.3. Mechlorethamine gel
4.4. HDAC Inhibitors
4.5. Monoclonal Antibodies
4.6. Localized Radiation Therapy
4.7. Extracorporeal Photopheresis
4.8. Others
4.9. Pipeline Analysis
4.9.1. Phase III Drug
4.9.1.1. SGX301
4.9.1.2. Naloxone Hydrochloride Lotion 0.5%
4.9.2. Tabular Representation of Phase I and II Drug Pipeline

Chapter 5. Global Mycosis Fungoides (MF) Market, by Geography
5.1. Overview
5.2. North America MF Market Analysis, 2017 – 2027
5.2.1. North America MF Market, by Treatment, 2017 – 2027 (US$ Mn)
5.2.2. North America MF Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe MF Market Analysis, 2017– 2027
5.3.1. Europe MF Market, by Treatment, 2017 – 2027 (US$ Mn)
5.3.2. Europe MF Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific MF Market Analysis, 2017 – 2027
5.4.1. Asia Pacific MF Market, by Treatment, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific MF Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America MF Market Analysis, 2017 – 2027
5.5.1. Latin America MF Market, by Treatment, 2017 – 2027 (US$ Mn)
5.5.2. Latin America MF Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa MF Market Analysis, 2017 – 2027
5.6.1. MEA MF Market, by Treatment, 2017 – 2027 (US$ Mn)
5.6.2. MEA MF Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Astellas Pharma
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Bayer AG
6.3. Dover Medical and Scientific Equipment, Ltd.
6.4. Elorac, Inc.
6.5. Kyowa Kirin, Inc.
6.6. Macopharma
6.7. Sanofi SA
6.8. Soligenix, Inc.
6.9. Varian Medical Systems
6.10. Yaupon Therapeutics

* Here we are using MF as a short form of Mycosis Fungoides

FIG. 1 Mycosis Fungoides (MF) Market: Research Methodology
FIG. 2 MF: Market Segmentation
FIG. 3 Global MF Market, by Treatment, 2018 (US$ Mn)
FIG. 4 Global MF Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global MF Market, by Key Players, 2018
FIG. 7 Global Topical Steroids Market for MF, 2017 – 2027 (US$ Mn)
FIG. 8 Global Mechlorethamine Gel Market for MF, 2017 – 2027 (US$ Mn)
FIG. 9 Global HDAC Inhibitors Market for MF, 2017 – 2027 (US$ Mn)
FIG. 10 Global Monoclonal Antibodies Market for MF, 2017– 2027 (US$ Mn)
FIG. 11 Global Localized Radiation Therapy Market for MF, 2017 – 2027 (US$ Mn)
FIG. 12 Global Extracorporeal Photopheresis Market for MF, 2017 – 2027 (US$ Mn)
FIG. 13 Global Other Treatment Market for MF, 2017 – 2027 (US$ Mn)
FIG. 14 U.S. MF Market, 2017 – 2027 (US$ Mn)
FIG. 15 Canada MF Market, 2017 – 2027 (US$ Mn)
FIG. 16 U.K. MF Market, 2017 – 2027 (US$ Mn)
FIG. 17 Germany MF Market, 2017 – 2027 (US$ Mn)
FIG. 18 Rest of Europe MF Market, 2017 – 2027 (US$ Mn)
FIG. 19 China MF Market, 2017– 2027 (US$ Mn)
FIG. 20 Japan MF Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest of Asia Pacific MF Market, 2017 – 2027 (US$ Mn)
FIG. 22 Brazil MF Market, 2017 – 2027 (US$ Mn)
FIG. 23 Mexico MF Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Latin America MF Market, 2017 – 2027 (US$ Mn)
FIG. 25 GCC MF Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest of Middle East and Africa MF Market, 2017 – 2027 (US$ Mn)

TABLE 1 Global Mycosis Fungoides (MF) Market Portraiture
TABLE 2 Global MF Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 3 Global MF Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America MF Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 5 North America MF Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe MF Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 7 Europe MF Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific MF Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific MF Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America MF Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America MF Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa MF Market, by Treatment, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa MF Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Astellas Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Dover Medical and Scientific Equipment, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Elorac, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Kyowa Kirin, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Macopharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Soligenix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Varian Medical Systems: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Yaupon Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)